BioSpace News Archive

Nearly eight months after leaving his post as head of R&D at Johnson & Johnson, Mathai Mammen has found a new job as CEO of cancer focused FogPharma.

With several recent milestones, Intellia Therapeutics is setting a solid foundation for gene editing in rare diseases with an eye toward broader patient populations.

HUTCHMED has completed the rolling submission of its New Drug Application to the FDA for fruquintinib, its candidate for refractor metastatic colorectal cancer.

Ravi B. Parikh discussed how new FDA guidance on accelerated approval for cancer drugs will affect the space.

Henlius announced its 2022 annual results. In 2022, Henlius’ revenue reached about RMB3.2147 billion, representing an increase of 91.1% YoY, primarily due to sales revenue and licensing revenue generated by the successive commercialisation of various products.

Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new a

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid Diagnostics” or “Lucid”) announced that, yesterday, the MolDX Program (“MolDX”) published a Future Effective Local Coverage Determination (“LCD”) L39256, on molecular testing for esophageal precancer and cancer in Medicare beneficiaries, to become effective May 14, 2023.

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, reported fourth quarter and full year 2022 financial results and provided a corporate update.

NightHawk Biosciences, a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, provided strategic, financial, and operational updates for the year ended December 31, 2022.